Immutep Ltd (ASX:IMM)'s Marc Voigt speaks with Proactive at the ASX Small and Mid Cap Conference - September 2021. The company's focused on the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Its current lead product candidate is eftilagimod alpha, a soluble LAG-3 fusion protein (LAG-3Ig).
Immutep with Proactive at the ASX Small and Mid Cap Conference
